A221 A RETROSPECTIVE ANALYSIS OF PATIENTS WITH BIOPSY PROVEN NASH IN AN URBAN CENTRE.

Fatty Liver Disease (FLD) has become the most common liver disease in Canada with at least 25% of the population afflicted. With that number on the rise, the need for non-invasive tools for diagnosis and management has become vital. We sought to gain a better understanding of the population of patients affected with FLD in order to better understanding of the burden of disease on the community. We also compared liver fibrosis diagnosed via liver biopsy to those diagnosed with fibroscan (liver stiffness). 67 patients who had undergone a Liver Biopsy for confirmative diagnosis of NASH (non-alcoholic steatohepatitis) and staging of liver fibrosis. All Liver biopsies with were conducted at one facility and interpreted by a liver pathologist. Fibroscan tests were conducted at a separate facility and liver stiffness was measured in kilopascals. Data was collected and retrospectively analysed for: patient demographics, fibroscan values, and Liver Biopsy report. Only patients with NAS≥2 (NASH Activity Score) were included in the study. The primary reason for referral for all 67 patients was an elevated ALT discovered by family physicians. Of the 67, 41 males, and 26 females. Mean age for males was 48.39, and females 52.46. Of the 67 patients studied, 65 underwent both a fibroscan and biopsy with a mean time of 161.46 days in between the two tests. Fibroscan: Mean LS was 11.60kPa, with 11.60kPa, and 11.30kPa for males and females, respectively. (Table 2 for gender breakdown). 39 of the 67 patients underwent serial fibroscans. Liver Biopsy: 6 of 7 patients with NAS=2 had significant fibrosis by Brunt. NAS score correlated to LS with P-value of 0.021. Only 2 patients underwent serial liver biopsies. (Refer to Table 1 for fibrosis stages by Brunt.) Based on our study cohort, more males at a younger age were effected by NASH. A discrepancy was found between fibrosis staging by fibroscan vs. biopsy. Meanwhile, NAS score strongly correlated to LS suggesting that LS proves to be a useful non-invasive tool to diagnose and monitor patients with NASH. Fibrosis Staging by Liver Stiffness (kPa) vs Fibrosis (Brunt/4). Figure 1: Assessment of Fibrosis by Liver Stiffness (kPa) vs. NASH Activity Score (NAS). None

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.